78 related articles for article (PubMed ID: 14647387)
1. Specific cytotoxic T cells eliminate cells producing neutralizing antibodies.
Planz O; Seiler P; Hengartner H; Zinkernagel RM
Nature; 2003 Nov; 426(6965):474. PubMed ID: 14647387
[No Abstract] [Full Text] [Related]
2. Specific cytotoxic T cells eliminate B cells producing virus-neutralizing antibodies [corrected].
Planz O; Seiler P; Hengartner H; Zinkernagel RM
Nature; 1996 Aug; 382(6593):726-9. PubMed ID: 8751445
[TBL] [Abstract][Full Text] [Related]
3. In vivo selection of neutralization-resistant virus variants but no evidence of B cell tolerance in lymphocytic choriomeningitis virus carrier mice expressing a transgenic virus-neutralizing antibody.
Seiler P; Senn BM; Bründler MA; Zinkernagel RM; Hengartner H; Kalinke U
J Immunol; 1999 Apr; 162(8):4536-41. PubMed ID: 10201992
[TBL] [Abstract][Full Text] [Related]
4. Nonneutralizing antibodies binding to the surface glycoprotein of lymphocytic choriomeningitis virus reduce early virus spread.
Hangartner L; Zellweger RM; Giobbi M; Weber J; Eschli B; McCoy KD; Harris N; Recher M; Zinkernagel RM; Hengartner H
J Exp Med; 2006 Aug; 203(8):2033-42. PubMed ID: 16880253
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of memory CTL responses by T helper cells and CD40-CD40 ligand: antibodies provide the key.
Bachmann MF; Hunziker L; Zinkernagel RM; Storni T; Kopf M
Eur J Immunol; 2004 Feb; 34(2):317-26. PubMed ID: 14768036
[TBL] [Abstract][Full Text] [Related]
6. Antiviral immune responses in gene-targeted mice expressing the immunoglobulin heavy chain of virus-neutralizing antibodies.
Hangartner L; Senn BM; Ledermann B; Kalinke U; Seiler P; Bucher E; Zellweger RM; Fink K; Odermatt B; Bürki K; Zinkernagel RM; Hengartner H
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12883-8. PubMed ID: 14569006
[TBL] [Abstract][Full Text] [Related]
7. Protracted course of lymphocytic choriomeningitis virus WE infection in early life: induction but limited expansion of CD8+ effector T cells and absence of memory CD8+ T cells.
Belnoue E; Fontannaz-Bozzotti P; Grillet S; Lambert PH; Siegrist CA
J Virol; 2007 Jul; 81(14):7338-50. PubMed ID: 17494081
[TBL] [Abstract][Full Text] [Related]
8. Parameters governing exhaustion of rare T cell-independent neutralizing IgM-producing B cells after LCMV infection.
Zellweger RM; Hangartner L; Weber J; Zinkernagel RM; Hengartner H
Eur J Immunol; 2006 Dec; 36(12):3175-85. PubMed ID: 17125146
[TBL] [Abstract][Full Text] [Related]
9. Evaluating antigen-specific cytotoxic T lymphocyte responses by a novel mouse granzyme B ELISPOT assay.
Ewen CL; Rong J; Kokaji AI; Bleackley RC; Kane KP
J Immunol Methods; 2006 Jan; 308(1-2):156-66. PubMed ID: 16375915
[TBL] [Abstract][Full Text] [Related]
10. Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus.
Eschli B; Zellweger RM; Wepf A; Lang KS; Quirin K; Weber J; Zinkernagel RM; Hengartner H
J Virol; 2007 Nov; 81(21):11650-7. PubMed ID: 17699567
[TBL] [Abstract][Full Text] [Related]
11. Antiviral antibodies attenuate T-cell-mediated immunopathology following acute lymphocytic choriomeningitis virus infection.
Wright KE; Buchmeier MJ
J Virol; 1991 Jun; 65(6):3001-6. PubMed ID: 1709692
[TBL] [Abstract][Full Text] [Related]
12. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antiviral antibodies reduce hematogenic viral spread but not antiviral cytotoxic T cell induction and subsequent immunopathology.
Battegay M; Seiler P; Hunziker L; Wolf K; Zinkernagel RM
J Infect Dis; 2001 May; 183(9):1425-7. PubMed ID: 11294679
[No Abstract] [Full Text] [Related]
14. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
15. Elimination of chronic viral infection by blocking CD27 signaling.
Matter M; Odermatt B; Yagita H; Nuoffer JM; Ochsenbein AF
J Exp Med; 2006 Sep; 203(9):2145-55. PubMed ID: 16923852
[TBL] [Abstract][Full Text] [Related]
16. Immune responses in interleukin-2-deficient mice.
Kündig TM; Schorle H; Bachmann MF; Hengartner H; Zinkernagel RM; Horak I
Science; 1993 Nov; 262(5136):1059-61. PubMed ID: 8235625
[TBL] [Abstract][Full Text] [Related]
17. B cell responses and immune memory.
Slifka MK; Ahmed R
Dev Biol Stand; 1998; 95():105-15. PubMed ID: 9855420
[No Abstract] [Full Text] [Related]
18. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL.
Matter M; Mumprecht S; Pinschewer DD; Pavelic V; Yagita H; Krautwald S; Borst J; Ochsenbein AF
Eur J Immunol; 2005 Nov; 35(11):3229-39. PubMed ID: 16231287
[TBL] [Abstract][Full Text] [Related]
19. Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.
Messer RJ; Dittmer U; Peterson KE; Hasenkrug KJ
Proc Natl Acad Sci U S A; 2004 Aug; 101(33):12260-5. PubMed ID: 15297622
[TBL] [Abstract][Full Text] [Related]
20. On the immunocompetence of H-2 incompatible irradiation bone marrow chimeras.
Zinkernagel RM; Althage A; Callahan G; Welsh RM
J Immunol; 1980 May; 124(5):2356-65. PubMed ID: 6444970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
